GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » INmune Bio Inc (NAS:INMB) » Definitions » Price-to-Tangible-Book

INmune Bio (INmune Bio) Price-to-Tangible-Book

: 6.95 (As of Today)
View and export this data going back to 2019. Start your Free Trial

As of today (2024-04-19), INmune Bio's share price is $8.37. INmune Bio's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $1.21. Hence, INmune Bio's Price to Tangible Book Ratio of today is 6.95.

The historical rank and industry rank for INmune Bio's Price-to-Tangible-Book or its related term are showing as below:

INMB' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.61   Med: 8.8   Max: 10.44
Current: 6.92

During the past 8 years, INmune Bio's highest Price to Tangible Book Ratio was 10.44. The lowest was 2.61. And the median was 8.80.

INMB's Price-to-Tangible-Book is ranked worse than
82.58% of 1223 companies
in the Biotechnology industry
Industry Median: 2.7 vs INMB: 6.92

A closely related ratio is called PB Ratio. As of today, INmune Bio's share price is $8.37. INmune Bio's Book Value per Sharefor the quarter that ended in Dec. 2023 was $2.13. Hence, INmune Bio's P/B Ratio of today is 3.94.


INmune Bio Price-to-Tangible-Book Historical Data

The historical data trend for INmune Bio's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

INmune Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Tangible-Book
Premium Member Only Premium Member Only Premium Member Only 8.80 10.44 2.86 2.61 9.34

INmune Bio Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Tangible-Book Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.61 2.99 4.77 4.32 9.34

Competitive Comparison

For the Biotechnology subindustry, INmune Bio's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


INmune Bio Price-to-Tangible-Book Distribution

For the Biotechnology industry and Healthcare sector, INmune Bio's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where INmune Bio's Price-to-Tangible-Book falls into.



INmune Bio Price-to-Tangible-Book Calculation

INmune Bio's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Dec. 2023 )
=8.37/1.205
=6.95

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


INmune Bio Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of INmune Bio's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


INmune Bio (INmune Bio) Business Description

Traded in Other Exchanges
N/A
Address
225 NE Mizner Boulevard, Suite 640, Boca Raton, FL, USA, 33432
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.
Executives
Scott Juda director 325 N. LARCHMONT BLVD, SUITE 375, LOS ANGELES CA 90004
Timothy J Schroeder director 2690 DEVILS BACKBONE ROAD, CINCINNATI OH 45233
David J Moss 10 percent owner, officer: CFO, Treasurer & Secretary C/O PEGASI ENERGY RESOURCES CORPORATION, 218 N. BROADWAY, SUITE 204, TYLER TX 75702
Raymond Joseph Tesi director, 10 percent owner, officer: President & CEO 476 MASSACHUSETTS AVE, UNIT 2, BOSTON MA 02118
Mark William Lowdell 10 percent owner, officer: Chief Scientific Officer THE OAK, WLX ROAD, BEAUMONT X0 CO16 0AT
Linda F Powers 10 percent owner 7600 WISCONSIN AVENUE, SUITE 700, BETHESDA MD 20814
James Kelly Ganjei director 10609 RIVER OAKS LANE, POTOMAC MD 20859
Marcia Allen director P.O. BOX 399, 2600 W. HOMESTEAD CIRCLE, WILSON WY 83014
Edgardo Jr Baracchini director C/O METABASIS THERAPEUTICS, 9390 TOWNE CENTRE DRIVE, BLDG. 300, SAN DIEGO CA 92121
Xencor Inc 10 percent owner 465 N. HALSTEAD ST., SUITE 200, PASADENA CA 91107
David Edmund Szymkowski director 241 WEST PALM AVENUE, MONROVIA CA 91016

INmune Bio (INmune Bio) Headlines

From GuruFocus

INmune Bio Inc (INMB) Reports Q3 2023 Financial Results

By GuruFocus Research 11-01-2023